Brief: Orexo Q1 EBITDA Swinga To Profit Of SEK 2.8 Mln

Orexo AB

28/04/2022 07:20

April 28 (Reuters) - Orexo AB  ORX.ST :
    * OREXO INTERIM REPORT Q1 2022
    * Q1 TOTAL NET REVENUES OF SEK 159.4 M (132.3)
    * Q1 EBITDA OF SEK 2.8 M (-23.9)
    * FINANCIAL OUTLOOK 2022 • DUE TO THE CONTINUING PANDEMIC
THE
BUPRENORPHINE/ NALOXONE MARKET WILL SHOW A GROWTH PACE IN LINE
WITH 2021, AND REACH A LEVEL OF 5-8 PERCENT
    * FINANCIAL OUTLOOK 2022: ZUBSOLV® NET SALES IN USD WILL
DECLINE
SLIGHTLY IN H1 2022 VERSUS H2 2021. IN H2 ZUBSOLV® NET SALES IN
USD WILL INCREASE COMPARING TO H1.
    * FINANCIAL OUTLOOK 2022: OPEX WILL DECLINE FROM 2021 TO SEK
650-700 M WITH THE CURRENT BUSINESS PLANS AND ACTIVITY LEVEL IN
LEGAL PROCESSES
    * FINANCIAL OUTLOOK 2022:  US PHARMA EBIT WILL EXCEED 50
PERCENT
ON A FULL YEAR BASIS

Source text for Eikon:  ID:nWkr1NF3b6 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))